Nasdaq gnlx.

WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad ...

Nasdaq gnlx. Things To Know About Nasdaq gnlx.

GNLX | Complete Genelux Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Genelux Corporation Common Stock (GNLX) Real-Time Quotes | Nasdaq Real-Time: GNLX Edit my quotes Genelux Corporation Common Stock (GNLX) 0 Add to Portfolio GNLX GNLX REAL TIME GNLX... Genelux Corporation (NASDAQ:GNLX) fell 8.7% to $10.83. Chegg, Inc. (NYSE:CHGG) shares declined 8.2% to $9.60. Morgan Stanley downgraded Chegg from Equal-Weight to Underweight and lowered the price ...WESTLAKE VILLAGE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication of positive topline ...As of this writing, Genelux Corp (NASDAQ:GNLX) shares are trading at above $22.30 with a 52-week range of $5.35 to $39.27, giving the company a market capitalization of more than $527 million. 2 ...

Shares of Genelux Corporation ( GNLX 3.11%) were up by as much as 20.8% for the week on Thursday, according to data provided by S&P Global Market Intelligence. The healthcare company closed last ...WebAug 28, 2023 · WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ... GNLX stock had a volatile day of trading on September 19, 2023, with significant fluctuations in its price. The stock opened at $21.93 and ranged from $21.93 to $25.85 throughout the day. The trading volume for GNLX on September 19 was 14,269 shares, considerably lower than the average volume of 124,690 shares over the past …

Genelux Corp (NASDAQ:GNLX) 14.07 Delayed Data As of 3:59pm ET -0.37 / -2.56% Today’s Change 5.35 Today ||| 52-Week Range 40.98 -- Year-to-Date Quote Profile News Charts Forecasts Financials...

WESTLAKE VILLAGE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO ...WebBack to GNLX Overview. Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or ...FN Media Group Presents USA News Group News Commentary . Vancouver, BC – October 11, 2023 – USA News Group – Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A recent study found a nearly 80% global increase in the number of under-50s getting diagnosed with cancer …NVIDIA Corporation Common Stock. $435.70 -0.93 -0.21%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ...Explore new charts. Discover historical prices for GNLX stock on Yahoo Finance. View daily, weekly or monthly format back to when Genelux Corporation stock was issued.

Genelux has filed to go public with an IPO on the NASDAQ. 1 year ago - SEC. Get a real-time Genelux Corporation (GNLX) stock price quote with breaking news, …

Genelux (NASDAQ:GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer. The company is currently ...

WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on ...Nov 30, 2023 · Genelux Corp (NASDAQ: GNLX) has experienced a rise in its stock price by 11.85 compared to its previous closing price of 10.46. However, the company has seen a gain of 12.72% in its stock price over the last five trading days. GlobeNewsWire reported 2023-09-07 that WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) — Genelux […] Find the latest Earnings Report Date for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.Find the latest Financials data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com. IPO preview: IPOs that could start trading next week include biopharma Genelux Corporation (NASDAQ:GNLX) and tech firm Beamr Imaging Ltd . The quiet periods on Corebridge Financial ...

Mar 27, 2023 · Genelux ( NASDAQ: GNLX) is a recently IPO-ed phase 3 stage cancer therapeutics company. Its business is designing “oncolytic viral immunotherapies that are designed to generate a personalized ... Genelux Corporation (NASDAQ:GNLX) declined 11.7% to $14.95. NatWest Group plc (NYSE:NWG) shares fell 11.5% to $4.49 after the company reported third-quarter earnings and lowered its full-year net ...WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares of the Company's common stock at a purchase price of $20.00 per share, for gross proceeds of approximately $18 million, …Check if GNLX Stock has a Buy or Sell Evaluation. GNLX Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Genelux Corporation News.2 days ago · Genelux IPO prices at bottom of range. Genelux Corp. priced its initial public offering at $6 a share, the low end of its $6 to $7 a share range, for its stock market debut Thursday on the Nasdaq under the symbol GNLX. With 2.5 million sha... 11 months ago - Market Watch. Jul 28, 2023 · Shares of Genelux ( GNLX -7.61%) were up 14.8% for the week, as of 9:30 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech company's stock ...

Genelux Corporation is a late clinical-stage public company (Nasdaq: GNLX) developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the …WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ...

Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25%. Key Insights Significant control over Genelux by retail investors …So far, 2023 has been a great year for Genelux Corporation (NASDAQ:GNLX), which has seen positive results from trials of its lead therapy Olvi-Vec (olvimulogene nanivacirepvec) that’s primarily ...WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 ...Jul 20, 2023 · WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ... On September 26, an intriguing development occurred in the world of finance. Aladar Szalay, a prominent figure within Genelux (NASDAQ:GNLX), made a significant move by selling off 16,591 shares of the company. The transaction amounted to a staggering $462,000, as revealed in a recently filed Form 4 with the U.S. Securities and …GNLX Genelux Corporation Genelux Corporation Announces Pricing of Initial Public Offering. WESTLAKE VILLAGE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation ('Genelux' or 'the ...WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 ...Nov 27, 2023 · Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. Analyst Price Forecast Suggests 230.81% Upside As of November 1 ...

WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad ...

WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President ...

Select time range to see more trades: Last 100 Trades. After Hours Time (ET) After Hours Price. After Hours Share Volume. 18:25:17. $5.8.In terms of stock performance, immunotherapy developer Genelux (NASDAQ:GNLX) has been the hands-down winner, with shares up an impressive 417% from their IPO price as of Monday's close.WebIPO preview: IPOs that could start trading next week include biopharma Genelux Corporation (NASDAQ:GNLX) and tech firm Beamr Imaging Ltd . The quiet periods on Corebridge Financial ...GNLX GNLX Genelux Corp NASDAQ 20.01 -0.03 -0.15% After Hours: 20.01 0 0.00% 16:01 10/19 EDT OPEN 20.00 PREV CLOSE 20.04 HIGH 20.40 LOW 20.00 VOLUME 101.28K …WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares of the Company's common stock at a purchase price of $20.00 per share, for gross proceeds of approximately $18 million, …Genelux Corporation (NASDAQ:GNLX) gained 12.9% to $30.82. Franchise Group, Inc. (NASDAQ:FRG) jumped 11.8% to $25.44. Franchise Group revealed the receipt of an unsolicited non-binding proposal to ...WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...Web52 Week Range 5.35 - 40.98. Market Cap $622.89M. Shares Outstanding 26.18M. Public Float 18.26M. Beta 1.10. Rev. per Employee $749.20K. P/E Ratio N/A. EPS -$0.58. Yield N/A.Based on analysts offering 12 month price targets for GNLX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. Sign in to your ...

Posted by Techdows on Nov 28th, 2023. HC Wainwright initiated coverage on shares of Genelux ( NASDAQ:GNLX – Free Report) in a research note issued to investors on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $35.00 target price on the stock. A number of other brokerages also recently …WebStructure Therapeutics Inc. American Depositary Shares (GPCR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Genelux Corporation Common Stock (GNLX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Nov 7, 2023 · The average price predicted for Genelux Corp (GNLX) by analysts is $36.00, which is $22.03 above the current market price. The public float for GNLX is 18.34M, and at present, short sellers hold a 4.76% of that float. On November 07, 2023, the average trading volume of GNLX was 223.78K shares. Top 5 AI Stocks to Buy for 2023. Instagram:https://instagram. who owns modelo especialfree nftetrade margin calculatorbuybackboss reviews WESTLAKE VILLAGE, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication in Frontiers in ...WebWESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad ... sales roseone dollar coin 1921 value Genelux (NASDAQ:GNLX) director Szalay Aladar continued to dispose of his stake in the biopharmaceutical company. Aladar sold 42,263 shares of indirect ownership, held by The Szalay 2010 Retained ... silver dollar 1979 value Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian ...In connection with the offering, the Company’s shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “GNLX” on January 26, 2023 subject to final approval ...